First Time Loading...

Sio Gene Therapies Inc
NASDAQ:SIOX

Watchlist Manager
Sio Gene Therapies Inc Logo
Sio Gene Therapies Inc
NASDAQ:SIOX
Watchlist
Price: 0.478 USD 1.7% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

SIOX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. [ Read More ]

The intrinsic value of one SIOX stock under the Base Case scenario is 0.623 USD. Compared to the current market price of 0.478 USD, Sio Gene Therapies Inc is Undervalued by 23%.

Key Points:
SIOX Intrinsic Value
Base Case
0.623 USD
Undervaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sio Gene Therapies Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SIOX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Sio Gene Therapies Inc

Provide an overview of the primary business activities
of Sio Gene Therapies Inc.

What unique competitive advantages
does Sio Gene Therapies Inc hold over its rivals?

What risks and challenges
does Sio Gene Therapies Inc face in the near future?

Has there been any significant insider trading activity
in Sio Gene Therapies Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sio Gene Therapies Inc.

Provide P/S
for Sio Gene Therapies Inc.

Provide P/E
for Sio Gene Therapies Inc.

Provide P/OCF
for Sio Gene Therapies Inc.

Provide P/FCFE
for Sio Gene Therapies Inc.

Provide P/B
for Sio Gene Therapies Inc.

Provide EV/S
for Sio Gene Therapies Inc.

Provide EV/GP
for Sio Gene Therapies Inc.

Provide EV/EBITDA
for Sio Gene Therapies Inc.

Provide EV/EBIT
for Sio Gene Therapies Inc.

Provide EV/OCF
for Sio Gene Therapies Inc.

Provide EV/FCFF
for Sio Gene Therapies Inc.

Provide EV/IC
for Sio Gene Therapies Inc.

Show me price targets
for Sio Gene Therapies Inc made by professional analysts.

What are the Revenue projections
for Sio Gene Therapies Inc?

How accurate were the past Revenue estimates
for Sio Gene Therapies Inc?

What are the Net Income projections
for Sio Gene Therapies Inc?

How accurate were the past Net Income estimates
for Sio Gene Therapies Inc?

What are the EPS projections
for Sio Gene Therapies Inc?

How accurate were the past EPS estimates
for Sio Gene Therapies Inc?

What are the EBIT projections
for Sio Gene Therapies Inc?

How accurate were the past EBIT estimates
for Sio Gene Therapies Inc?

Compare the revenue forecasts
for Sio Gene Therapies Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sio Gene Therapies Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sio Gene Therapies Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sio Gene Therapies Inc compared to its peers.

Compare the P/E ratios
of Sio Gene Therapies Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Sio Gene Therapies Inc with its peers.

Analyze the financial leverage
of Sio Gene Therapies Inc compared to its main competitors.

Show all profitability ratios
for Sio Gene Therapies Inc.

Provide ROE
for Sio Gene Therapies Inc.

Provide ROA
for Sio Gene Therapies Inc.

Provide ROIC
for Sio Gene Therapies Inc.

Provide ROCE
for Sio Gene Therapies Inc.

Provide Gross Margin
for Sio Gene Therapies Inc.

Provide Operating Margin
for Sio Gene Therapies Inc.

Provide Net Margin
for Sio Gene Therapies Inc.

Provide FCF Margin
for Sio Gene Therapies Inc.

Show all solvency ratios
for Sio Gene Therapies Inc.

Provide D/E Ratio
for Sio Gene Therapies Inc.

Provide D/A Ratio
for Sio Gene Therapies Inc.

Provide Interest Coverage Ratio
for Sio Gene Therapies Inc.

Provide Altman Z-Score Ratio
for Sio Gene Therapies Inc.

Provide Quick Ratio
for Sio Gene Therapies Inc.

Provide Current Ratio
for Sio Gene Therapies Inc.

Provide Cash Ratio
for Sio Gene Therapies Inc.

What is the historical Revenue growth
over the last 5 years for Sio Gene Therapies Inc?

What is the historical Net Income growth
over the last 5 years for Sio Gene Therapies Inc?

What is the current Free Cash Flow
of Sio Gene Therapies Inc?

Financials

Balance Sheet Decomposition
Sio Gene Therapies Inc

Current Assets 47.3m
Cash & Short-Term Investments 46.1m
Receivables 400k
Other Current Assets 800k
Current Liabilities 2.2m
Accounts Payable 200k
Accrued Liabilities 1.5m
Other Current Liabilities 500k
Efficiency

Earnings Waterfall
Sio Gene Therapies Inc

Revenue
0 USD
Operating Expenses
-29.4m USD
Operating Income
-29.4m USD
Other Expenses
540k USD
Net Income
-28.8m USD

Free Cash Flow Analysis
Sio Gene Therapies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SIOX Profitability Score
Profitability Due Diligence

Sio Gene Therapies Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

24/100
Profitability
Score

Sio Gene Therapies Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

SIOX Solvency Score
Solvency Due Diligence

Sio Gene Therapies Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Sio Gene Therapies Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SIOX Price Targets Summary
Sio Gene Therapies Inc

There are no price targets for SIOX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SIOX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SIOX Price
Sio Gene Therapies Inc

1M 1M
-
6M 6M
-89%
1Y 1Y
-89%
3Y 3Y
-98%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
0.478
52w Low
0.0413
52w High
0.417
Price Metrics
Average Annual Return -50.92%
Standard Deviation of Annual Returns 14.19%
Max Drawdown -100%
Shares Statistics
Market Capitalization 3.2m USD
Shares Outstanding 73 975 196
Percentage of Shares Shorted 0.13%

SIOX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Sio Gene Therapies Inc Logo
Sio Gene Therapies Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.2m USD

Dividend Yield

0%

Description

Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company is headquartered in New York City, New York and currently employs 42 full-time employees. The company went IPO on 2015-06-11. The firm is focused on developing gene therapies for neurodegenerative diseases. The firm is developing a pipeline of product candidates for the treatment of these debilitating diseases, including GM1 gangliosidosis, GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, and Parkinson's disease. The firm is under three clinical-stage programs, AXO-AAV-GM1, AXO-AAV-GM2 and AXO-Lenti-PD. The AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene. The AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. The AXO-AAV-GM2 program utilizes dual AAV vectors to deliver functional copies of both the HEXA gene and the HEXB gene. The AXO-Lenti-PD program for the treatment of Parkinson's disease, comprised of the ProSavin Phase 0.5 study.

Contact

NEW YORK
New York City
130 West 42Nd Street, 26Th Floor
+18777464891.0
https://siogtx.com/

IPO

2015-06-11

Employees

42

Officers

CEO, CFO, Chief Accounting Officer, General Counsel & Director
Mr. David W. Nassif J.D.

See Also

Discover More
What is the Intrinsic Value of one SIOX stock?

The intrinsic value of one SIOX stock under the Base Case scenario is 0.623 USD.

Is SIOX stock undervalued or overvalued?

Compared to the current market price of 0.478 USD, Sio Gene Therapies Inc is Undervalued by 23%.